Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 58 of the 60 references it cites were found in a registry or an index.

Which interventions offer best value for money in primary prevention of cardiovascular disease

Open access

Abstract

BACKGROUND: Despite many decades of declining mortality rates in the Western world, cardiovascular disease remains the leading cause of death worldwide. In this research we evaluate the optimal mix of lifestyle, pharmaceutical and population-wide interventions for primary prevention of cardiovascular disease. METHODS AND FINDINGS: In a discrete time Markov model we simulate the ischaemic heart disease and stroke outcomes and cost impacts of intervention over the lifetime of all Australian men and women, aged 35 to 84 years, who have never experienced a heart disease or stroke event. Best value for money is achieved by mandating moderate limits on salt in the manufacture of bread, margarine and cereal. A combination of diuretic, calcium channel blocker, ACE inhibitor and low-cost statin, for everyone with at least 5% five-year risk of cardiovascular disease, is also cost-effective, but lifestyle interventions aiming to change risky dietary and exercise behaviours are extremely poor value for money and have little population health benefit. CONCLUSIONS: There is huge potential for improving efficiency in cardiovascular disease prevention in Australia. A tougher approach from Government to mandating limits on salt in processed foods and reducing excessive statin prices, and a shift away from lifestyle counselling to more efficient absolute risk-based prescription of preventive drugs, could cut health care costs while improving population health.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0041842

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The cost-effectiveness acceptability frontier, shown for values of the cost-effectiveness threshold up to $150,000/DALY. Addition of the interventions that are not visible on the graph, is not optimal until much higher cost-effectiveness thresholds (dietary advice above $2.4 million/DALY and phytosterol margarine above $6.7 million/DALY).
Figure 1 The cost-effectiveness acceptability frontier, shown for values of the cost-effectiveness threshold up to $150,000/DALY. Addition of the interventions that are not visible on the graph, is not optimal until much higher cost-effectiveness thresholds (dietary advice above $2.4 million/DALY and phytosterol margarine above $6.7 million/DALY).CC BY · PubMed Central
Figure 2 The cost-effectiveness of current practice and the optimal intervention pathway (NB. CCB – calcium channel blocker; ACEi – ACE inhibitor; CHHP – community heart health program). Interventions are added to the mix in order of cost-effectiveness, thus the pathway reflects the efficiency frontier. The pathway is shown as a solid line where the incremental cost-effectiveness of adding an intervention to the mix is under the cost-effectiveness threshold of $50,000/DALY, and shown as a dashed line where the addition of the next intervention is not cost-effectiveness (i.e. it exceeds the threshold of $50,000/DALY).
Figure 2 The cost-effectiveness of current practice and the optimal intervention pathway (NB. CCB – calcium channel blocker; ACEi – ACE inhibitor; CHHP – community heart health program). Interventions are added to the mix in order of cost-effectiveness, thus the pathway reflects the efficiency frontier. The pathway is shown as a solid line where the incremental cost-effectiveness of adding an intervention to the mix is under the cost-effectiveness threshold of $50,000/DALY, and shown as a dashed line where the addition of the next intervention is not cost-effectiveness (i.e. it exceeds the threshold of $50,000/DALY).CC BY · PubMed Central
Figure 3 Sensitivity of the optimal pathway to increased and decreased discounting (5% and 0%), to the addition of other non-cardiovascular health care costs in added years of life, the measurement of health gain in QALYs rather than DALYs, and to a reduction in the cost of statin drugs to the much lower price in New Zealand (NB. the order of interventions is altered only by the reduction in statin price, with statins becoming a more cost-effective intervention option than the blood pressure-lowering drugs).
Figure 3 Sensitivity of the optimal pathway to increased and decreased discounting (5% and 0%), to the addition of other non-cardiovascular health care costs in added years of life, the measurement of health gain in QALYs rather than DALYs, and to a reduction in the cost of statin drugs to the much lower price in New Zealand (NB. the order of interventions is altered only by the reduction in statin price, with statins becoming a more cost-effective intervention option than the blood pressure-lowering drugs).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Research works printed but not linked: 1

  1. S Lim, 2005, Priority setting for the primary prevention of coronary heart disease and stroke in Australia [PhD thesis].

Cited by

See all 97

Metadata

Authors
Cobiac, L. J., Magnus, A., Lim, S., Barendregt, J. J., Carter, R., & Vos, T.
Affiliations
  • The University of Queensland (AU)
  • Deakin University (AU)
  • Institute for Health Metrics and Evaluation (US)
Corresponding author
Cobiac, Linda J.
Venue
PLoS ONE
Published
2012-07-23
Volume
7
Issue
7
Pages
e41842
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2010609873
Cited by
97
References
60
Citations by year
2025: 3 · 2023: 5 · 2022: 4 · 2021: 5 · 2020: 4 · 2019: 8 · 2018: 5 · 2017: 16 · 2016: 14 · 2015: 11 · 2014: 11 · 2013: 7 · 2012: 3
FWCI
9.88
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • Griffith Research Online (submittedVersion, cc-by)
Funders
  • Medical Research Council
  • National Health and Medical Research Council (351558)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Keywords
cardiovascular disease prevention, primary prevention, cost-effectiveness, statins, lifestyle intervention, ischemic heart disease, stroke, diuretics, calcium channel blockers, ACE inhibitors, health care costs, Australia
MeSH terms
Adult, Aged, Aged, 80 and over, Blood Pressure, Cardiovascular Diseases, Cholesterol, Cost-Benefit Analysis, Female, Humans, Life Style, Male, Middle Aged, Primary Prevention, Health Care Sector

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Which interventions offer best value for money in primary prevention of cardiovascular disease. https://app.cochat.ai/papers/10.1371/journal.pone.0041842
The paper
Cobiac, L. J., Magnus, A., Lim, S., Barendregt, J. J., Carter, R., & Vos, T. (2012). Which interventions offer best value for money in primary prevention of cardiovascular disease. PLoS ONE. https://doi.org/10.1371/journal.pone.0041842

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.